Brainsway reports positive results in multiple sclerosis study

The safety and efficacy trial tested a non-invasive proprietary coil to stimulate the motor cortex for the lower limbs in patients with advanced multiple sclerosis.

Brainsway Ltd. (TASE:BRIN) today reported positive results in a safety and efficacy trial of its non-invasive proprietary coil to stimulate the motor cortex for the lower limbs in patients with advanced multiple sclerosis.

The double blind trial was conducted by Advanced Technologies Innovation Distribution SrL on 23 patients at INSPE Medical Center in Milan. Half the patients were treated by the device over three weeks, and half received a placebo.

Success was measured as the ability to walk ten meters in six minutes, a standard measurement under the Modified Ashworth Scale (MAS). The patients who received the treatment showed a clear statistical improvement compared with the patients who received the placebo. No side effects were recorded.

The researchers cautioned that the results must be confirmed in a larger multicenter trial.

Brainsway's share price rose 10% by mid-afternoon to NIS 18.83, giving a market cap of NIS 222 million.

Published by Globes [online], Israel business news - www.globes-online.com - on October 23, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018